Vit C
PreclinicalSmall molecule
Vit C is one of 49 small molecule programs targeting Oxidative Stress. It is currently in Preclinical.
3
Indications
6
Total Trials
0
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
51 competitors in Oxidative Stress
#DrugCompanyPhaseTrials
1Amidate
PfizerApproved
Precose
BayerApproved
Amaryl
SanofiApproved
Actos
TakedaApproved
Versed
CConrado Roberto Hoffmann Filho
Approved
Zocor
OOrganon and Co
Approved
Januvia
ZZydus Therapeutics Inc.
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Bacterial Infections1 trial
Age1 trial
Comparative Evaluation of Vitamin C and Injectable-platelet Rich Fibrin in the Management of Thin Gingival Phenotype
Unknown status·—·Phase 4·NCT05841303·13 enrolled
Rickets1 trial
Effectiveness of Vitamin C Supplementation in Treatment of Rickets
Completed·—·Phase 2/3·NCT05310760·88 enrolled
Oxidative Stress1 trial
Conditioning1 trial
1 more indication
Vasoplegia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Vit C. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- MMedical University of Vienna